The Food and Drug Administration has been meeting with OpenAI to discuss the agency’s use of AI, according to sources with knowledge of the meetings. The meetings appear to be part of a broader effort at the FDA to use this technology to speed up the drug approval process. “Why does it take over 10 years for a new drug to come to market?” wrote FDA commissioner Marty Makary on X on Wednesday. To be clear, using AI to assist in final drug reviews would represent a chance to compress just a small part of the notoriously long drug-development timeline. The vast majority of drugs fail before ever coming up for FDA review.